Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
P/E ratio (year end quote, basic EPS) 253.37 259.61 - - P/E ratio (year end quote, diluted EPS) 253.37 259.61 - - Silexion Therapeutics Dividend Calendar Silexion Therapeutics Calendar Indices ...
After hours: February 27 at 5:50:12 PM EST Loading Chart for CTOR ...
After hours: 7:59:02 p.m. EST ...
After hours: February 18 at 6:56:12 p.m. EST ...
Pre-market: 8:31:30 am GMT-5 ...
After hours: 7:54:49 pm GMT-5 ...
After hours: 7:55:45 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback